ArticleExperimental and therapeutic medicine2018
miR-6852 serves as a prognostic biomarker in colorectal cancer and inhibits tumor growth and metastasis by targeting TCF7.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Tissue micro-RNAs associated with colorectal cancer prognosis: a systematic review.Molecular biology reports · 2021Pooled it
- A-to-I-edited miR-1251-5p restrains tumor growth and metastasis in lung adenocarcinoma through regulating TCF7-mediated Wnt signaling pathway.Discover oncology · 2024Article
- Long non-coding RNA TRPM2 antisense RNA as a potential therapeutic target promotes tumorigenesis and metastasis in esophageal cancer.Bioengineered · 2022Article
- Circular RNA expression profiles in human bronchial epithelial cells treated with beryllium sulfate.Toxicology research · 2021Article
- Splice and Dice: Intronic microRNAs, Splicing and Cancer.Biomedicines · 2021Review
- LncRNA TCF7 Promotes Epithelial Ovarian Cancer Viability, Mobility and StemnessFrontiers in oncology · 2021Article
- Long noncoding RNA MAFG-AS1 promotes proliferation, migration and invasion of hepatocellular carcinoma cells through downregulation of miR-6852.Experimental and therapeutic medicine · 2019Article
- MicroRNA-6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1.Experimental and therapeutic medicine · 2019Article
- MEIS2 promotes cell migration and invasion in colorectal cancer.Oncology reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRs) are have been demonstrated to serve important functions in the genesis of human cancer, including colorectal cancer (CRC). The role of miR-6852 in CRC remains unknown. In this study, it was demonstrated that miR-6852 was underexpressed in CRC tissues compared with adjacent normal tissues. Moreover, the expression of miR-6852 was negatively correlated with CRC metastasis, whereas positively correlated with patient prognosis. It was revealed that the overexpression of miR-6852 significantly inhibited the proliferation and invasion of CRC cells. miR-6852 overexpression reduced CRC cells in the S phase. TCF7 was identified to be a direct target of miR-6852 in CRC cells. Overexpression of miR-6852 significantly inhibited the mRNA and protein levels of TCF7 in CRC cells. Furthermore, TCF7 was highly expressed in CRC tissues and cell lines. TCF7 expression was negatively correlated with miR-6852 levels in CRC tissues. Finally, knockdown of TCF7 significantly suppressed the proliferation and invasion of CRC cells. Taken together, the results of the present study indicated that miR-6852 serves as a tumor suppressor in CRC through targeting TCF7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.